Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma

Blood

Volumn 90, Issue 10, 1997, Pages 4201-4205

  Verdonck, Leo F ^a   Dekker, Adriaan W ^a   Lokhorst, Henk M ^a   Petersen, Eefke J ^a   Nieuwenhuis, H Karel ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CHLORMETHINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RELAPSE; TREATMENT OUTCOME;

EID: 0030831750     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.10.4201     Document Type: Article

References (27)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphoma. Semin Oncol 20:75, 1993
2. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT: The treatment of indolent lymphomas: watchful waiting V aggressive combined modality treatment. Semin Hematol 25:11, 1988
3. Cheson BD: New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas. Semin Oncol 20:96, 1993
4. Horning SJ: Treatment approaches to the low-grade lymphomas. Blood 83:881, 1994
5. Weisdorf DJ, Andersen JW, Glick JH, Oken MM: Survival after relapse of low-grade non-Hodgkin's lymphoma: Implications for marrow transplantation. J Clin Oncol 10:942, 1992
6. Johnson PWM, Rohatiner AZS, Whelan JS, Price CGA, Love S, Lim J, Matthews J, Norton AJ, Amess JAL, Lister TA: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140, 1995
7. Armitage JO: Bone marrow transplantation for indolent lymphomas. Semin Oncol 20:136, 1993
8. van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath R, Romaguera JF, McLaughlin P, Korbling M, Deisseroth AB, Cabanillas FF, Champlin RE: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 13:1096, 1995
9. Rosenberg SA, Berard CW, Brown BW, Burke J, Dorfman RF, Glatstein E, Hoppe RT, Simon R: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for Clinical Usage (the Non-Hodgkin's Lymphoma Pathologic Classification Project). Cancer 49:2112, 1982
10. Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK: Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 83:3090, 1994
11. Verdonck LF, Dekker AW, van Kempen ML, Punt K, van Unnik JAM, van Peperzeel HA, de Gast GC: Intensive cytotoxic therapy followed by autologous bone marrow transplantation for non-Hodgkin's lymphoma of high-grade malignancy. Blood 65:984, 1985
12. Thomas ED, Storb R, Clift RA, Fefer M, Johnson FL, Neiman PF, Lerner KG, Glucksberg H, Buckner CD: Bone marrow transplantation. N Engl J Med 292:895, 1975
13. van Besien K, Rowlings PA, Sobocinski KA, Philips G, Vose J. McCarthy P, Klein JP, Champlin R, Horowitz MM: Allogeneic bone marrow transplantation for low grade lymphoma. Blood 86:209a, 1995 (abstr, suppl 1)
14. Lundberg JH, Hansen RM, Chitambar CR, Lawton CA, Gottlieb M, Anderson T, Ash RC: Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 9:1848, 1991
15. Jones RJ, Armbinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649, 1991
16. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplantation Group Registry Data. J Clin Oncol 10:1690, 1992
17. Shepherd JD, Barnett MJ, Connors JM, Spinelli JJ, Sutherland HJ, Kingemann H-G, Nantel SH, Reece DE, Currie CJ, Philips GL: Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma. Bone Marrow Transplant 12:591, 1993
18. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F, Cummings G, Sensenbrenner LL: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050, 1994
19. Rohatiner AZS, Johnson PWM, Price CGA, Arnott SJ, Amess JAL, Norton AJ, Dorey E, Adams K, Whelan JS, Matthews J, MacCallum PK, Oza AM, Lister TA: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177, 1994
20. Schouten HC, Colombat Ph, Verdonck LF, Gorin NC, Björkstrand B, Taghipour G, Goldstone AH: Autologous bone marrow transplantation for low-grade non-Hodgkin's lymphoma: The European Bone Marrow Transplant Group experience. Ann Oncol 5:S147, 1994
21. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Woo D, Niland JC, Forman SJ: High-dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony stimulating factor mobilized peripheral blood stem cells. J Clin Oncol 12:2176, 1994
22. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Gisselbrecht C, Coiffier B: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257, 1995
23. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780, 1996
24. Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gonin R, Miller KB, Rudders RA, Freeman A, Blake K, Coral F, Nadler LM, Ritz J: Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 10:1191, 1992
25. Jacobs P, Wood L, Fullard L, Waldmann H, Hale G: T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 13:763, 1994
26. Bunjes D, Hertenstein B, Wiesneth M, Stefanic M, Novotny J, Duncker C, Heit W, Arnold R, Heimpel H: In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: Comparison with cyclosporin/methotrexate. Bone Marrow Transplant 15:563, 1995
27. Verdonck LF, Putten WLJ van, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JMM, van Oers MHJ, Haak HL, Schots R, Dekker AW, de Gast GC, Löwenberg B: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045, 1995